Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.87 USD
Change Today +0.12 / 3.20%
Volume 83.1K
FCSC On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

fibrocell science inc (FCSC) Snapshot

Open
$3.86
Previous Close
$3.75
Day High
$3.90
Day Low
$3.85
52 Week High
03/5/15 - $5.99
52 Week Low
12/15/14 - $2.28
Market Cap
158.1M
Average Volume 10 Days
90.5K
EPS TTM
$-0.67
Shares Outstanding
40.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for FIBROCELL SCIENCE INC (FCSC)

fibrocell science inc (FCSC) Related Bloomberg News

View More Bloomberg News

fibrocell science inc (FCSC) Related Businessweek News

No Related Businessweek News Found

fibrocell science inc (FCSC) Details

Fibrocell Science, Inc., an autologous cell therapy company, focuses on developing treatments for skin and connective tissue diseases with unmet medical needs. The company, through its proprietary autologous fibroblast technology, develops azficel-T, which is in Phase II clinical trials for the treatment of vocal cord scarring and restrictive burn scarring. It is also conducting orphan gene therapy program that is in pre-clinical development stage for the treatment of recessive dystrophic epidermolysis bullosa; and gene therapy program, which is in pre-clinical development stage for linear scleroderma. The company has collaboration agreement with Intrexon Corporation for using genetically-modified autologous fibroblast cells to target proteins in patients with rare genetic skin and connective tissue disorders; and University of California, Los Angeles to focus on discoveries and technologies related to stem cells and regenerative cells in human skin. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was founded in 1995 and is headquartered in Exton, Pennsylvania.

50 Employees
Last Reported Date: 03/13/15
Founded in 1995

fibrocell science inc (FCSC) Top Compensated Officers

Chairman of the Board, Chief Executive Office...
Total Annual Compensation: $454.8K
Vice President of Human Resources and Busines...
Total Annual Compensation: $199.4K
Vice President of Scientific Affairs
Total Annual Compensation: $188.0K
Vice President of Quality
Total Annual Compensation: $148.8K
Compensation as of Fiscal Year 2013.

fibrocell science inc (FCSC) Key Developments

Fibrocell Science, Inc. Adopts Amendment to the Bylaws

On April 20, 2015, the board of directors of Fibrocell Science, Inc. adopted an amendment to the fourth amended and restated bylaws of the company. The bylaws amendment became effective on April 20, 2015. The purpose of the bylaws amendment was to clarify the required vote for matters being considered by the company's stockholders.

Fibrocell Science Appoints Keith A. Goldan as Senior Vice President and Chief Financial Officer

On March 18, 2015, Fibrocell Science, Inc. announced the appointment of Keith A. Goldan as Chief Financial Officer, Senior Vice President, Treasurer and Corporate Secretary of the company, effective immediately. Kimberly M. Smith, who has served as Interim Chief Financial Officer, Treasurer and Corporate Secretary of the company since October 2014 has resigned from these positions and will remain at the company as Controller, a position she has held since January 2014. Prior to joining the company, from November 2008 to March 2014, Mr. Goldan, age 44, served as Senior Vice President and Chief Financial Officer of NuPathe Inc.

Fibrocell Science, Inc. Reports Unaudited Consolidated Financial Results for the Fourth Quarter and Fiscal Year Ended December 31, 2014

Fibrocell Science, Inc. reported unaudited consolidated financial results for the fourth quarter and fiscal year ended December 31, 2014. For the quarterly period ended December 31, 2014, the company reported a diluted net loss of $0.09 per share, compared to a diluted net loss of $0.15 per share for the same period in 2013. Revenues for each of the fourth quarters of 2014 and 2013 were insignificant. The company used $6.8 million in cash for operations during the fourth quarter of 2014, as compared to $4.0 million in the fourth quarter of 2013. Operating loss was $6.2 million for the quarter ended December 31, 2014 as compared to $5.7 million for the same period in 2013. The increase of $0.5 million was due primarily to increases in selling, general and administrative expenses and research and development expenses of $0.3 million and $1.2 million, respectively, offset by a decrease in cost of sales of $0.9 million. Loss before income taxes was $3,372,000 against $5,742,000 for the same period of last year. Net loss was $3,372,000 against $5,742,000 for the same period of last year. For the twelve months ended December 31, 2014, the company reported a diluted net loss of $0.70 per share, compared to a diluted net loss of $1.12 per share for the same period in 2013. Revenues for the twelve months of 2014 and 2013 were insignificant. The company used $22.3 million in cash for operations during 2014, as compared to $20.1 million for the comparable period in 2013. Operating loss was $30.0 million for the twelve months of 2014 compared to $30.5 million for the same period in 2013. The decrease of $0.5 million was due to primarily to a decrease in cost of sales of $5.2 million, and offset by increases in selling, general and administrative expenses and research and development expenses of $2.2 million and $2.4 million, respectively. Loss before income taxes was $25,650,000 against $31,554,000 for the same period of last year. Net loss was $25,650,000 against $31,554,000 for the same period of last year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FCSC:US $3.87 USD +0.12

FCSC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioTime Inc $5.72 USD -0.16
Bluebird Bio Inc $136.26 USD -3.82
Organovo Holdings Inc $5.19 USD +0.12
Sangamo BioSciences Inc $14.70 USD -0.84
Vertex Pharmaceuticals Inc $133.20 USD -2.62
View Industry Companies
 

Industry Analysis

FCSC

Industry Average

Valuation FCSC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 851.2x
Price/Book 5.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 642.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FIBROCELL SCIENCE INC, please visit www.fibrocellscience.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.